FDA nixes increased production at ViroPharma; Indian pharma market growing to $55B;

 @FiercePharma: Lovenox copycat sucks market share from Sanofi. Article | Follow @FiercePharma

> ViroPharma, a specialty pharmaceutical company, said U.S. health regulators declined to approve industrial-scale manufacturing of its genetic disorder drug Cinryze, sending its shares down 17 percent. Report

> The Indian pharma market looks poised to grow to $55 billion by 2020, up from $12.6 billion in 2009, according to a new McKinsey & Co. report. News

> China's State Food and Drug Administration and the Shanghai Public Security Bureau are investigating a Beijing pharmaceutical plant allegedly producing a counterfeit version of the drug Avastin. Article

> PhRMA is meeting with Indian officials to review a recent proposal for using compulsory licensing to assure that prices--particularly for cancer and AIDS meds--remain affordable. Story

> Dr Reddy's Laboratories, India's No. 2 drugmaker by sales, reported a 32 percent jump in net profit for the quarter ending September, topping estimates. Item

> Specialty pharmaceutical company Warner Chilcott won the FDA nod for its new low-dose oral contraceptive, Lo Loestrin Fe, sending its shares up 3 percent in pre-market trade. Warner Chilcott release | Report

Biotech News

 @FierceBiotech: Aastrom puts hopes in promising CLI therapy. Story | Follow @FierceBiotech

 @JohnCFierce: Interesting remark in Economist story on biosimilars: Lots of litigation ahead as Roche/Genentech, Amgen defend turf. Article | Follow @JohnCFierce

> After FDA's ARNA decision, what's next for obesity drugs? News

> Waksal back to deal-making mode, snags Three Rivers for $100M. Report

> Timeline: A look back at Arena's lorcaserin. Article 

> FDA throws up a tricky roadblock for Arena's lorcaserin. Item 

> Billionaire Allen helps inject $25M into Seattle's Omeros. News

> Genzyme says Sanofi's bid is $4.2B short of reality. Story

Biotech IT News

> Supercomputer to boost drug development, personalized medicine research. Report 

> Hamburg seeks something better than randomized trials for drug approvals. Story 

> CRO Westat goes digital for clinical signoffs. Article 

> Transcept sweats FDA reaction to sleeping pill data. Item 

> Simulator provides early view of trial operations. Report 

> Savvy users set up to shift among cloud providers. News

And Finally... Pfizer is less than thrilled by what it's seen so far about "Love & Other Drugs," a movie portrayal of a drug-industry sales rep. Report

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.